# Ansun Biopharma, Inc.: Research, San Diego, United States

> Ansun Biopharma, Inc.: Ansun Biopharma, Inc. Based in San Diego, United States. Founded 2003. What Millionrounds holds on them, and what we have not seen.

Source: https://millionrounds.com/startup/ansun-biopharma-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Ansun Biopharma, Inc.

Ansun Biopharma, Inc.

Funding reported Last round: Series B

Research San Diego, United States

Company summary

- **Founded:** 2003 23 years old
- **Team:** 21 11 to 50 people
- **Funding reported:** $213M in dollars
- **Last round:** Series B Oct 2019

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Ansun Biopharma, Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Ansun Biopharma, Inc.

Ansun Biopharma, Inc.

is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2003 by virologists Dr. Mang Yu and Dr. Fang Fang, the company focuses on developing innovative, host-directed anti-viral biologics aimed at treating severe viral infections and cancer. With a dedicated team of around 25 to 27 employees, Ansun's mission is to create therapeutics that address unmet medical needs, particularly for vulnerable patient populations. The company's lead product, DAS181, is a multi-function sialidase fusion protein designed to block viral infections by cleaving sialic acid receptors from host respiratory cells. DAS181 is currently in Phase 3 clinical trials for treating Parainfluenza Virus and advancing in Phase IIB trials for severe Influenza. Ansun also explores therapies for oncology and autoimmune diseases using its sialidase platform. The company has secured significant funding, including a $50 million contract from the NIH and multiple financing rounds, to support its development efforts.

## What company datasets say Ansun Biopharma, Inc. raised

Funding, as reported

Reported in all **$213M** in dollars

Rounds **7**

Last round **Series B**

Last round size **$7.9M**

Last round date **Oct 2019**

Investors listed **11**

## Founders and team

From the SEC filings it signed: 2 on the team.

- **Nancy Chang** Executive Officer, Director i
- **Yining Zhao** Executive Officer i

On the board, as filed i *Aimin Wu* *Allen Chao* *Dave Chenn* *Donald Payne* *Karen Liu* *Michael Chang* *Michael Chao* *Yi Shi*

## On 2 portfolio pages

Investors who name them

- [Virtus Inspire Ventures](https://millionrounds.com/fund/vi-ventures)
- [BroadVision](https://millionrounds.com/fund/broadvision)

Each firm lists Ansun Biopharma, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care host-directed therapy sialidase enzyme host receptor targeting biotechnology research host-targeted antiviral healthcare das181 biopharmaceutical development immunocompromised patients viral entry inhibition respiratory infection therapy sialic acid biology pharmaceuticals influenza treatment respiratory viruses

Built with from their website

Google Maps WhatsApp Business Chat Priority Hints Slider Revolution WordPress.org Microsoft Exchange Microsoft 365 Font Awesome Apache MySQL

+8 more

YouTube Apache HTTP Server Outlook Microsoft 365 Apps & Services PHP Viewport Meta Barracuda Email Security Service Mobile Friendly

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731
- **Region:** California
- **Revenue:** $8.0M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/ansun-biopharma)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Ansun Biopharma, Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)